Successful Phase 2 clinical trial of ISLA-101 achieves anti-dengue activity in humans
• Highly encouraging phase 2a/b top-line results advocate for the continued clinical development of ISLA-101 in dengue virus
• ISLA-101 associated with meaningful reduction in both viremia (viral load) and symptoms in preventative cohort
• Treatment cohort demonstrated signals of drug effect
• Investor webinar scheduled for Tuesday, 17 June at 11:00am AEST
Ann: Successful Phase 2 clinical trial of ISLA-101, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.67M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.0¢ | 17.0¢ | $107.4K | 601.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 58773 | 1 |
View Market Depth
| Last trade - 15.55pm 13/06/2025 (20 minute delay) ? |
| ILA (ASX) Chart |